Cathay Capital and Sofinnova Partners led a $59m Series C funding round in TISSIUM.

Cathay Capital, a private equity firm, and Sofinnova Partners, an independent venture capital firm, led a $59m Series C funding round in TISSIUM, a developer of biodegradable sealants and adhesives for surgical-wound closure. “With the closing of our Series C financing round, TISSIUM is well-positioned to take the next steps to commercialization. This funding significantly bolsters our ability to move with speed towards our goal of enhancing tissue reconstruction for patients. This financing will contribute significantly to TISSIUM’s ability to take advantage of the variety of opportunities we have to advance our innovation in this space," Christophe Bancel, TISSIUM CEO.